Foresight logo

  • Foresight® Carrier Screen empowers patients with information by identifying couples at risk of passing down serious heritable conditions to their child

  • Foresight screens for more than 175 genetic conditions affecting approximately 1 in 300 pregnancies with >99% accuracy

  • Carrier screening is cost-effective relative to conventional screening methods


Fact Sheets and Product Info:

Closeup of happy couple

Executive Summary

 Download PDF


About Carrier Screening:

The goal of carrier screening is to detect couples who are at risk of passing down serious inherited conditions.

Universal carrier screening for cystic fibrosis and spinal muscular atrophy is recommended by American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists. (ACOG).1,2


About Foresight Carrier Screen:

We’ve designed the Foresight Carrier Screen to maximize detection rates for the diseases that matter the most.

  • Unmatched At-Risk Couple Detection
    Have the utmost confidence you aren’t missing couples at risk with the highest published at-risk couple detection rate for serious inherited conditions (1 in 22 couples)3

  • Superior Technology
    Unmatched detection rates for the vast majority of genes on our panel (>99% across ethnicities) means you can trust both positive and negative results.

  • Seamless Patient Care With Myriad Complete
    Whether its automated results reporting and tracking, merged reports for couples, or on-demand patient education, our solutions are designed to help the patient through the screening process.


1. Prior, Thomas W. 2008. “Carrier Screening for Spinal Muscular Atrophy.” Genetics in Medicine: Official Journal of the American College of Medical Genetics 10 (November). The American College of Medical Genetics: 840.

2. Committee Opinion No. 690 Summary: Carrier Screening in the Age of Genomic Medicine.” 2017. Obstetrics and Gynecology 129 (3): 595–96.

3. Hogan et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clinical Chemistry 2018; doi:10.1373/clinchem.2018.286823.